Oral vitamin C × serum urate: direct evidence links remain unverified in this record

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhat is the selected urate question?Required	The selected wording is “Serum-urate reduction.” The existing subclaim is linked separately from its verdict record. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Existing urate wording and verdict record, and parent/separate-verdict boundaries	Material needed: The parent question on recurrent-flare prevention is not changed into this question or made into a new claim. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionWhat does the preserved C54 mean?Required	The existing urate subclaim is C·54; its note says it is the separate surrogate verdict in 3019. The parent verdict is deferred with an empty score. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Existing C54, separate-verdict note for 3019, and parent deferral/empty score	Material needed: The existing subclaim is preserved without new efficacy grading or completed content review. It is not overwritten by the parent grade or vice versa. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhat materials were used for this view?Required	The complete stored Korean/English 3020 summary, subclaim, parent evidence and bibliography were used. Original tables from 3019 are not merged. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Stored 3020 summary and urate wording, unread external materials and no merger with 3019	Material needed: The relevant urate-trial result tables and bibliography are not directly linked in 3020; external abstracts, full text, registration and plans are unread, with access not attempted. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionHow is the relationship with 3019 retained?Required	References to 3019 in the existing subclaim and parent notes are retained. This view concerns the existing urate question in 3020. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Separate-verdict note, original values, citation and duplication limits	Material needed: Content, numbers and conditions from 3019 are not combined as new reading or independent replication. Related unique trial and participant totals remain unverified. This records needed materials; no new research was executed.
5	Unverified	Full text not readStored summary read	N05 · Evidence conditionWho was actually studied for urate reduction?Required	The selected subclaim records serum-urate reduction and the note about 3019, without population details. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Diagnosis, baseline urate, gout/non-gout status, age and selection	Material needed: Parent adults with established gout and PHS II male physicians or the group without prior gout are not transferred as the relevant urate-trial population. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWhat is linked about formulation and route?Required	The parent context is oral single-ingredient ascorbic acid and a purified nutrient; feedstock and manufacture remain unverified. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Parent oral single-ingredient C context and the selected trial’s product, salt and excipients	Material needed: This is not elevated to verified product specifications for the relevant urate trial. Trial-specific tablet/capsule, salt, excipients and product identity remain unverified. This records needed materials; no new research was executed.
7	Unverified	Full text not readStored summary read	N07 · Evidence conditionWhat are dose, frequency and actual exposure?Required	This 3020 account lacks dose, frequency and actual-exposure records for the selected urate question. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Dose, dosing and adherence in the selected urate trial	Material needed: The parent’s not-applicable dose for absent eligible human attack studies belongs to the attack question and is not transferred to the relevant urate dose. This records needed materials; no new research was executed.
8	Unverified	Full text not readStored summary read	N08 · Evidence conditionWhat are duration and measurement times?Required	Duration and measurement times for the urate trial are not linked in this 3020 account. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Dosing, follow-up and measurement times in the selected urate trial	Material needed: Urate-trial duration is not filled using the parent’s not-applicable duration or the long-term PHS II factorial-trial timeline. This records needed materials; no new research was executed.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionWhat are the comparator and concomitant medication?Required	The selected urate wording lacks comparator and concomitant-treatment specifications. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes	Material needed: The parent comparator for absent eligible attack evidence and PHS II C versus placebo are not transferred as comparisons in the relevant urate trial. This records needed materials; no new research was executed.
10	Unverified	Full text not readStored summary read	N10 · Evidence conditionWhat are allocation, design and blinding?Required	This 3020 account does not provide direct design or methods for the urate question. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Selected urate-trial design, allocation, concealment, baseline balance and blinding	Material needed: The double-blind factorial PHS II design is not inherited by the relevant urate trial; randomized or nonrandomized design is not newly established. This records needed materials; no new research was executed.
11	Unverified	Full text not readStored summary read	N11 · Evidence conditionHow was serum urate measured?Required	The original selected endpoint wording is serum-urate reduction. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Serum testing, units, methods, time points, final values and changes	Material needed: Methods, units, baseline, final values, changes, test conditions and blinding remain unverified. Gout diagnoses and attacks are not substituted. This records needed materials; no new research was executed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionWhat are the selected effect, P, CI and important difference?Required	Between-group numerical urate effects, P values and CIs are absent from this 3020 account. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Between-group urate effect, original intervals and important numerical difference	Material needed: PHS II gout HRs and diagnosis rates are not changed into urate effects. Values from 3019 or newly calculated effects/intervals do not fill the gaps. This records needed materials; no new research was executed.
13	Unverified	Full text not readStored summary read	N13 · Evidence conditionWhat are the selected sample, denominators and missingness?Required	This 3020 account lacks direct urate-trial sample, denominator and attrition tables. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Urate allocation, measurement, completion, analysis, group denominators and missingness	Material needed: The 14641 participants and PHS II allocation/prior-gout-excluded denominators are not transferred to the relevant urate trial; events and participants are not summed. This records needed materials; no new research was executed.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionWhat effect does the selected analysis estimate?Required	The selected urate-analysis model and population are absent from this 3020 account. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit	Material needed: The urate-analysis model is not filled using the post hoc PHS II gout analysis, HR model or prior-gout-excluded analysis. This records needed materials; no new research was executed.
15	Unverified	Full text not readStored summary read	N15 · Evidence conditionWhat are urate-outcome registration and prespecified hierarchy?Required	The selected wording lacks the identity of urate-trial registration and plans. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes	Material needed: NCT00270647 is a cited identifier for the original PHS II cardiovascular/cancer trial. It is not transferred as preregistration of the relevant urate trial; plans remain unread in this work. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionWhat is the background role of the post hoc PHS II report?Required	The Juraschek2022 PHS II report, PMID35575611, PMCIDPMC9437983 and DOI10.1093/ajcn/nqac140 are retained as parent background context. S01	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate	Material needed: The report’s 454/517, 262/290, HRs and self-reported diagnoses are not transferred as direct serum-urate evidence. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionWhat is the background role of the chronic-gout review?Required	The Dietary interventions for chronic gout2021 citation, PMID34767649, is a parent note that vitamin C trials did not measure attack frequency. S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Cochrane2021 citation, unmeasured attacks and exact included trials	Material needed: The brief note does not establish urate effects, denominators, included trials, funding or plans and is not counted as a new direct trial. This records needed materials; no new research was executed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionWhat is known about contrary/null results, doses and populations?Required	This 3020 account lacks positive/null urate-trial values and a complete condition-specific list. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Direct urate-trial positive/null findings, formulation, population, dose and intervals	Material needed: C54 alone does not establish consistent benefit or absence of null results. Gout-diagnosis findings are not transferred as conflicting urate results. This records needed materials; no new research was executed.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionAre independent replication and study totals established?Required	The selected note refers to a separate surrogate verdict in 3019; the preserved input for this view is 3020. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original urate reports, trial families, citation of 3019 and duplication	Material needed: Tables from 3019 are not combined as new independent replication. Parent PHS II/review material is not summed as urate trials or participants; unique totals remain unverified. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionDoes urate reduction establish diagnosis prevention, fewer attacks or drug replacement?Required	The existing account explains that urate reduction, attack prevention and standard-drug replacement each require separate evidence. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Separate questions for surrogate outcomes, clinical events and treatment replacement	Material needed: The surrogate C54 grade is not repurposed as a grade for recurrent clinical attacks, first-diagnosis prevention or drug replacement. This records needed materials; no new research was executed.
21	Unverified	Full text not readStored summary read	N21 · Evidence conditionWhat are long-term, dose and subgroup materials?Required	The selected wording lacks dose, duration and population details beyond urate reduction. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups	Material needed: Optimal dosing, sustained effects and population-specific effects are not filled using parent material or unmerged values from 3019. This records needed materials; no new research was executed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionWhat are selected-trial funding, products, employees and interests?Required	Funding, products and interests for the direct urate report are not linked in this 3020 account. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original urate-trial funding, products, packaging, employment and interests	Material needed: PHS II NIH and BASF/Pfizer/DSM support→I1 is retained as parent wording, not transferred as independence of the relevant urate trial. This records needed materials; no new research was executed.
23	Unverified	Full text not readStored summary read	N23 · Evidence conditionHow were harms collected for the selected exposure?Supplementary	Parent wording about high-dose oral C caution, gastrointestinal effects and limited event counts is retained as background. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Urate-trial exposure, event collection, denominators, stopping and duration	Material needed: Group-specific harms, collection, stopping and denominators for the selected urate trial remain unverified. Urate reduction is not used to judge safety. This records needed materials; no new research was executed.
24	Unverified	Full text not readStored summary read	N24 · Evidence conditionWhat is known about predisposition, concomitant treatment, long-term and rare harms?Supplementary	Existing oral caution is retained; detailed harm material for the selected exposure is absent. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure	Material needed: Specific interactions, causality, between-group risks, recovery after stopping and absence of long-term/rare harms remain unverified. No new incidence rate or verdict is created. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre the parent’s human-study indicator and selected axes distinguished?Required	The parent’s no-human-study indicator is enabled, while the narrative says human studies exist and the indicator should be disabled. Both original records are retained. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Disagreement between original indicator and narrative, and absent selected-subclaim axes	Material needed: This is not corrected or inherited as a urate axis or a judgment of 0 human studies overall. Axes were not originally recorded for the selected urate subclaim. This records needed materials; no new research was executed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionWhat records are the English subclaim, parent dates, deferral and empty corrections?Required	Serum-urate reduction, the note about 3019, C54, parent Korean/English text, deferral, empty score,2026-09-07 and empty correction/deliberation records are retained. Production date is distinguished from completed content review. S01 S02	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07	Material needed: Historical independent checks and the parent evidence date are not inherited as new urate full-text reading or completed content review. This records needed materials; no new research was executed.

No items match your search or filter.

26 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-07
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: The selected urate subclaim lacks population details. Parent adults with established gout and PHS II male physicians or the prior-gout-excluded group are not transferred as the relevant urate-trial population.
Ingredient, formulation and route: The parent’s oral single-ingredient ascorbic acid and purified-nutrient context is retained. Feedstock, manufacture and the relevant urate trial’s product, tablet/capsule, salt, excipients and identity remain unverified.
Dose: Dose, frequency, actual exposure and adherence for the relevant urate trial are not linked in this record. The parent’s not-applicable dose for absent eligible attack studies is not transferred to this question.
Comparator: Placebo, active comparison, urate medication, diet, additional supplementation, rescue treatment, changes and adherence for the relevant urate trial are not linked. Background PHS II C versus placebo is not transferred as a urate comparison.
Measured outcome: The selected wording is serum-urate reduction. Units, measurement methods, baseline/final/change values, analysis and numerical effects are not linked in this record and are not replaced by gout diagnoses or attacks.
Duration: Dosing, follow-up and measurement times for the selected urate trial are not linked. They are not filled using the parent’s not-applicable duration or the background long-term PHS II factorial-trial timeline.
Questions outside this scope: The original urate subclaim verdict C54 and note that it is a separate surrogate verdict in 3019 are retained. They remain separate from parent flare-verdict deferral and empty score and do not establish new scoring or completed clinical review.; This stored record concerns the existing urate question in 3020. Original tables, effects and conditions from 3019 are not imported to fill direct-evidence gaps or combined as new independent replication.; Full-cohort and prior-gout-excluded PHS II gout-diagnosis reports and the chronic-gout review are background context. Their events, HRs, participants, denominators and support are not repurposed as urate values, direct trials or independence.; Direct effects, P values, CIs, measurement units, denominators, analysis and prespecified plans for the selected urate question remain unverified. No new urate values, intervals, incidence rates, unit conversions or participant totals are calculated.; The parent’s no-human-study indicator is enabled, while its narrative says human studies exist. Both originals are retained; this disagreement is not inherited as a urate-question axis or a judgment of 0 human studies overall.; Urate, first gout diagnosis, recurrent attacks in established gout and standard-drug replacement are separate questions. Existing caution for high oral doses, gastrointestinal effects, kidney disease, stone risk and iron overload is retained without new safety conclusions or individual dosing guidance.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Background: Juraschek et al. 2022 · PHS II gout-diagnosis analysis

Official source

Material type: Parent post hoc gout-diagnosis report; not direct evidence for the selected urate question
Materials actually read: Stored summary read; external materials unread
Findings recorded in the stored summary: Background gout diagnoses: full-cohort 454/7329 versus 517/7312; HR0.88(95%CI0.77–0.99),P=.04. Prior-gout-excluded 262/6865 versus 290/6823; HR0.90(0.76–1.07),P=.23; rates 4.8 versus 5.4/1000 person-years. These values are not used as urate-reduction effects.
Record level: The parent report’s total 14,641, C7329/placebo7312, male physicians≥50 years and 6.5% prior gout are background information. The randomized factorial design, post hoc self-report and date imputation are not transferred as the relevant urate trial’s design, population, denominator or model.
Study overlap and independent replication: The background full-cohort and prior-gout-excluded PHS II analyses report the same original trial, not direct urate replication. The chronic-gout review and separate verdict 3019 are distinguished; unique urate-trial, participant and replication totals remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
External paper	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Protocol	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Statistical analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Funding, product support and COI material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This background report retains PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and cited NCT00270647. The original registration field is empty; the identifier, allocation and post hoc diagnoses are not transferred as preregistration or direct results of the selected urate trial. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.

S02 · Background: Dietary interventions for chronic gout · Cochrane 2021

PubMed

Material type: Parent citation-only chronic-gout review; not a direct urate trial
Materials actually read: Stored summary read; external materials unread
Findings recorded in the stored summary: The existing citation’s brief note records that vitamin C trials did not measure gout-attack frequency.
Record level: This is parent bibliographic context, PMID34767649. The brief note does not establish urate effects, denominators, included trials, support or plans and is not counted as a new direct trial or new participants.
Study overlap and independent replication: The background full-cohort and prior-gout-excluded PHS II analyses report the same original trial, not direct urate replication. The chronic-gout review and separate verdict 3019 are distinguished; unique urate-trial, participant and replication totals remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
External paper	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Protocol	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Statistical analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.
Funding, product support and COI material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	This is existing citation background, PMID34767649. External full text, inclusion, extraction and analysis materials are unread and remain separate from direct urate evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading.

Report counts versus independent study counts

The background full-cohort and prior-gout-excluded PHS II analyses report the same original trial, not direct urate replication. The chronic-gout review and separate verdict 3019 are distinguished; unique urate-trial, participant and replication totals remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What is the selected urate question?

Required materials and conditions: Existing urate wording and verdict record, and parent/separate-verdict boundaries
Conditions for verification: Original records on Existing urate wording and verdict record, and parent/separate-verdict boundaries must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Existing urate wording and verdict record, and parent/separate-verdict boundaries is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N02 · What does the preserved C54 mean?

Required materials and conditions: Existing C54, separate-verdict note for 3019, and parent deferral/empty score
Conditions for verification: Original records on Existing C54, separate-verdict note for 3019, and parent deferral/empty score must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Existing C54, separate-verdict note for 3019, and parent deferral/empty score is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N03 · What materials were used for this view?

Required materials and conditions: Stored 3020 summary and urate wording, unread external materials and no merger with 3019
Conditions for verification: Original records on Stored 3020 summary and urate wording, unread external materials and no merger with 3019 must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Stored 3020 summary and urate wording, unread external materials and no merger with 3019 is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N04 · How is the relationship with 3019 retained?

Required materials and conditions: Separate-verdict note, original values, citation and duplication limits
Conditions for verification: Original records on Separate-verdict note, original values, citation and duplication limits must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Separate-verdict note, original values, citation and duplication limits is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N05 · Who was actually studied for urate reduction?

Required materials and conditions: Diagnosis, baseline urate, gout/non-gout status, age and selection
Conditions for verification: Original records on Diagnosis, baseline urate, gout/non-gout status, age and selection must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Diagnosis, baseline urate, gout/non-gout status, age and selection is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N06 · What is linked about formulation and route?

Required materials and conditions: Parent oral single-ingredient C context and the selected trial’s product, salt and excipients
Conditions for verification: Original records on Parent oral single-ingredient C context and the selected trial’s product, salt and excipients must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Parent oral single-ingredient C context and the selected trial’s product, salt and excipients is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N07 · What are dose, frequency and actual exposure?

Required materials and conditions: Dose, dosing and adherence in the selected urate trial
Conditions for verification: Original records on Dose, dosing and adherence in the selected urate trial must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Dose, dosing and adherence in the selected urate trial is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N08 · What are duration and measurement times?

Required materials and conditions: Dosing, follow-up and measurement times in the selected urate trial
Conditions for verification: Original records on Dosing, follow-up and measurement times in the selected urate trial must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Dosing, follow-up and measurement times in the selected urate trial is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N09 · What are the comparator and concomitant medication?

Required materials and conditions: Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes
Conditions for verification: Original records on Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N10 · What are allocation, design and blinding?

Required materials and conditions: Selected urate-trial design, allocation, concealment, baseline balance and blinding
Conditions for verification: Original records on Selected urate-trial design, allocation, concealment, baseline balance and blinding must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Selected urate-trial design, allocation, concealment, baseline balance and blinding is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N11 · How was serum urate measured?

Required materials and conditions: Serum testing, units, methods, time points, final values and changes
Conditions for verification: Original records on Serum testing, units, methods, time points, final values and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Serum testing, units, methods, time points, final values and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N12 · What are the selected effect, P, CI and important difference?

Required materials and conditions: Between-group urate effect, original intervals and important numerical difference
Conditions for verification: Original records on Between-group urate effect, original intervals and important numerical difference must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Between-group urate effect, original intervals and important numerical difference is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N13 · What are the selected sample, denominators and missingness?

Required materials and conditions: Urate allocation, measurement, completion, analysis, group denominators and missingness
Conditions for verification: Original records on Urate allocation, measurement, completion, analysis, group denominators and missingness must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Urate allocation, measurement, completion, analysis, group denominators and missingness is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N14 · What effect does the selected analysis estimate?

Required materials and conditions: ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit
Conditions for verification: Original records on ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N15 · What are urate-outcome registration and prespecified hierarchy?

Required materials and conditions: Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes
Conditions for verification: Original records on Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N16 · What is the background role of the post hoc PHS II report?

Required materials and conditions: Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate
Conditions for verification: Original records on Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N17 · What is the background role of the chronic-gout review?

Required materials and conditions: Cochrane2021 citation, unmeasured attacks and exact included trials
Conditions for verification: Original records on Cochrane2021 citation, unmeasured attacks and exact included trials must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Cochrane2021 citation, unmeasured attacks and exact included trials is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N18 · What is known about contrary/null results, doses and populations?

Required materials and conditions: Direct urate-trial positive/null findings, formulation, population, dose and intervals
Conditions for verification: Original records on Direct urate-trial positive/null findings, formulation, population, dose and intervals must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Direct urate-trial positive/null findings, formulation, population, dose and intervals is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N19 · Are independent replication and study totals established?

Required materials and conditions: Original urate reports, trial families, citation of 3019 and duplication
Conditions for verification: Original records on Original urate reports, trial families, citation of 3019 and duplication must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original urate reports, trial families, citation of 3019 and duplication is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N20 · Does urate reduction establish diagnosis prevention, fewer attacks or drug replacement?

Required materials and conditions: Separate questions for surrogate outcomes, clinical events and treatment replacement
Conditions for verification: Original records on Separate questions for surrogate outcomes, clinical events and treatment replacement must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Separate questions for surrogate outcomes, clinical events and treatment replacement is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N21 · What are long-term, dose and subgroup materials?

Required materials and conditions: Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups
Conditions for verification: Original records on Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N22 · What are selected-trial funding, products, employees and interests?

Required materials and conditions: Original urate-trial funding, products, packaging, employment and interests
Conditions for verification: Original records on Original urate-trial funding, products, packaging, employment and interests must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original urate-trial funding, products, packaging, employment and interests is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N23 · How were harms collected for the selected exposure?

Required materials and conditions: Urate-trial exposure, event collection, denominators, stopping and duration
Conditions for verification: Original records on Urate-trial exposure, event collection, denominators, stopping and duration must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Supplementary
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Urate-trial exposure, event collection, denominators, stopping and duration is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N24 · What is known about predisposition, concomitant treatment, long-term and rare harms?

Required materials and conditions: Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure
Conditions for verification: Original records on Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Supplementary
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N25 · Are the parent’s human-study indicator and selected axes distinguished?

Required materials and conditions: Disagreement between original indicator and narrative, and absent selected-subclaim axes
Conditions for verification: Original records on Disagreement between original indicator and narrative, and absent selected-subclaim axes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Disagreement between original indicator and narrative, and absent selected-subclaim axes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

N26 · What records are the English subclaim, parent dates, deferral and empty corrections?

Required materials and conditions: Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07
Conditions for verification: Original records on Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07 must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Requirement and applicability: Required
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07 is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-22 · Public page/material version 1.0

Public-facing views and materials were prepared from the existing 26 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-07) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What is the selected urate question?

Current findings: The selected wording is “Serum-urate reduction.” The existing subclaim is linked separately from its verdict record.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The parent question on recurrent-flare prevention is not changed into this question or made into a new claim.
Required materials and conditions: Existing urate wording and verdict record, and parent/separate-verdict boundaries
Materials to obtain first: The parent question on recurrent-flare prevention is not changed into this question or made into a new claim.
Further research: Material needed: The parent question on recurrent-flare prevention is not changed into this question or made into a new claim. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Existing urate wording and verdict record, and parent/separate-verdict boundaries must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Existing urate wording and verdict record, and parent/separate-verdict boundaries is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N02 · What does the preserved C54 mean?

Current findings: The existing urate subclaim is C·54; its note says it is the separate surrogate verdict in 3019. The parent verdict is deferred with an empty score.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The existing subclaim is preserved without new efficacy grading or completed content review. It is not overwritten by the parent grade or vice versa.
Required materials and conditions: Existing C54, separate-verdict note for 3019, and parent deferral/empty score
Materials to obtain first: The existing subclaim is preserved without new efficacy grading or completed content review. It is not overwritten by the parent grade or vice versa.
Further research: Material needed: The existing subclaim is preserved without new efficacy grading or completed content review. It is not overwritten by the parent grade or vice versa. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Existing C54, separate-verdict note for 3019, and parent deferral/empty score must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Existing C54, separate-verdict note for 3019, and parent deferral/empty score is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N03 · What materials were used for this view?

Current findings: The complete stored Korean/English 3020 summary, subclaim, parent evidence and bibliography were used. Original tables from 3019 are not merged.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The relevant urate-trial result tables and bibliography are not directly linked in 3020; external abstracts, full text, registration and plans are unread, with access not attempted.
Required materials and conditions: Stored 3020 summary and urate wording, unread external materials and no merger with 3019
Materials to obtain first: The relevant urate-trial result tables and bibliography are not directly linked in 3020; external abstracts, full text, registration and plans are unread, with access not attempted.
Further research: Material needed: The relevant urate-trial result tables and bibliography are not directly linked in 3020; external abstracts, full text, registration and plans are unread, with access not attempted. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Stored 3020 summary and urate wording, unread external materials and no merger with 3019 must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Stored 3020 summary and urate wording, unread external materials and no merger with 3019 is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N04 · How is the relationship with 3019 retained?

Current findings: References to 3019 in the existing subclaim and parent notes are retained. This view concerns the existing urate question in 3020.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Content, numbers and conditions from 3019 are not combined as new reading or independent replication. Related unique trial and participant totals remain unverified.
Required materials and conditions: Separate-verdict note, original values, citation and duplication limits
Materials to obtain first: Content, numbers and conditions from 3019 are not combined as new reading or independent replication. Related unique trial and participant totals remain unverified.
Further research: Material needed: Content, numbers and conditions from 3019 are not combined as new reading or independent replication. Related unique trial and participant totals remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Separate-verdict note, original values, citation and duplication limits must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Separate-verdict note, original values, citation and duplication limits is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N05 · Who was actually studied for urate reduction?

Current findings: The selected subclaim records serum-urate reduction and the note about 3019, without population details.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Parent adults with established gout and PHS II male physicians or the group without prior gout are not transferred as the relevant urate-trial population.
Required materials and conditions: Diagnosis, baseline urate, gout/non-gout status, age and selection
Materials to obtain first: Parent adults with established gout and PHS II male physicians or the group without prior gout are not transferred as the relevant urate-trial population.
Further research: Material needed: Parent adults with established gout and PHS II male physicians or the group without prior gout are not transferred as the relevant urate-trial population. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Diagnosis, baseline urate, gout/non-gout status, age and selection must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Diagnosis, baseline urate, gout/non-gout status, age and selection is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N06 · What is linked about formulation and route?

Current findings: The parent context is oral single-ingredient ascorbic acid and a purified nutrient; feedstock and manufacture remain unverified.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: This is not elevated to verified product specifications for the relevant urate trial. Trial-specific tablet/capsule, salt, excipients and product identity remain unverified.
Required materials and conditions: Parent oral single-ingredient C context and the selected trial’s product, salt and excipients
Materials to obtain first: This is not elevated to verified product specifications for the relevant urate trial. Trial-specific tablet/capsule, salt, excipients and product identity remain unverified.
Further research: Material needed: This is not elevated to verified product specifications for the relevant urate trial. Trial-specific tablet/capsule, salt, excipients and product identity remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Parent oral single-ingredient C context and the selected trial’s product, salt and excipients must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Parent oral single-ingredient C context and the selected trial’s product, salt and excipients is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N07 · What are dose, frequency and actual exposure?

Current findings: This 3020 account lacks dose, frequency and actual-exposure records for the selected urate question.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The parent’s not-applicable dose for absent eligible human attack studies belongs to the attack question and is not transferred to the relevant urate dose.
Required materials and conditions: Dose, dosing and adherence in the selected urate trial
Materials to obtain first: The parent’s not-applicable dose for absent eligible human attack studies belongs to the attack question and is not transferred to the relevant urate dose.
Further research: Material needed: The parent’s not-applicable dose for absent eligible human attack studies belongs to the attack question and is not transferred to the relevant urate dose. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Dose, dosing and adherence in the selected urate trial must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Dose, dosing and adherence in the selected urate trial is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N08 · What are duration and measurement times?

Current findings: Duration and measurement times for the urate trial are not linked in this 3020 account.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Urate-trial duration is not filled using the parent’s not-applicable duration or the long-term PHS II factorial-trial timeline.
Required materials and conditions: Dosing, follow-up and measurement times in the selected urate trial
Materials to obtain first: Urate-trial duration is not filled using the parent’s not-applicable duration or the long-term PHS II factorial-trial timeline.
Further research: Material needed: Urate-trial duration is not filled using the parent’s not-applicable duration or the long-term PHS II factorial-trial timeline. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Dosing, follow-up and measurement times in the selected urate trial must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Dosing, follow-up and measurement times in the selected urate trial is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N09 · What are the comparator and concomitant medication?

Current findings: The selected urate wording lacks comparator and concomitant-treatment specifications.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The parent comparator for absent eligible attack evidence and PHS II C versus placebo are not transferred as comparisons in the relevant urate trial.
Required materials and conditions: Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes
Materials to obtain first: The parent comparator for absent eligible attack evidence and PHS II C versus placebo are not transferred as comparisons in the relevant urate trial.
Further research: Material needed: The parent comparator for absent eligible attack evidence and PHS II C versus placebo are not transferred as comparisons in the relevant urate trial. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Placebo, active comparator, urate medication, diet, supplements, rescue treatment and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N10 · What are allocation, design and blinding?

Current findings: This 3020 account does not provide direct design or methods for the urate question.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The double-blind factorial PHS II design is not inherited by the relevant urate trial; randomized or nonrandomized design is not newly established.
Required materials and conditions: Selected urate-trial design, allocation, concealment, baseline balance and blinding
Materials to obtain first: The double-blind factorial PHS II design is not inherited by the relevant urate trial; randomized or nonrandomized design is not newly established.
Further research: Material needed: The double-blind factorial PHS II design is not inherited by the relevant urate trial; randomized or nonrandomized design is not newly established. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Selected urate-trial design, allocation, concealment, baseline balance and blinding must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Selected urate-trial design, allocation, concealment, baseline balance and blinding is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N11 · How was serum urate measured?

Current findings: The original selected endpoint wording is serum-urate reduction.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Methods, units, baseline, final values, changes, test conditions and blinding remain unverified. Gout diagnoses and attacks are not substituted.
Required materials and conditions: Serum testing, units, methods, time points, final values and changes
Materials to obtain first: Methods, units, baseline, final values, changes, test conditions and blinding remain unverified. Gout diagnoses and attacks are not substituted.
Further research: Material needed: Methods, units, baseline, final values, changes, test conditions and blinding remain unverified. Gout diagnoses and attacks are not substituted. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Serum testing, units, methods, time points, final values and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Serum testing, units, methods, time points, final values and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N12 · What are the selected effect, P, CI and important difference?

Current findings: Between-group numerical urate effects, P values and CIs are absent from this 3020 account.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: PHS II gout HRs and diagnosis rates are not changed into urate effects. Values from 3019 or newly calculated effects/intervals do not fill the gaps.
Required materials and conditions: Between-group urate effect, original intervals and important numerical difference
Materials to obtain first: PHS II gout HRs and diagnosis rates are not changed into urate effects. Values from 3019 or newly calculated effects/intervals do not fill the gaps.
Further research: Material needed: PHS II gout HRs and diagnosis rates are not changed into urate effects. Values from 3019 or newly calculated effects/intervals do not fill the gaps. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Between-group urate effect, original intervals and important numerical difference must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Between-group urate effect, original intervals and important numerical difference is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N13 · What are the selected sample, denominators and missingness?

Current findings: This 3020 account lacks direct urate-trial sample, denominator and attrition tables.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The 14641 participants and PHS II allocation/prior-gout-excluded denominators are not transferred to the relevant urate trial; events and participants are not summed.
Required materials and conditions: Urate allocation, measurement, completion, analysis, group denominators and missingness
Materials to obtain first: The 14641 participants and PHS II allocation/prior-gout-excluded denominators are not transferred to the relevant urate trial; events and participants are not summed.
Further research: Material needed: The 14641 participants and PHS II allocation/prior-gout-excluded denominators are not transferred to the relevant urate trial; events and participants are not summed. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Urate allocation, measurement, completion, analysis, group denominators and missingness must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Urate allocation, measurement, completion, analysis, group denominators and missingness is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N14 · What effect does the selected analysis estimate?

Current findings: The selected urate-analysis model and population are absent from this 3020 account.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The urate-analysis model is not filled using the post hoc PHS II gout analysis, HR model or prior-gout-excluded analysis.
Required materials and conditions: ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit
Materials to obtain first: The urate-analysis model is not filled using the post hoc PHS II gout analysis, HR model or prior-gout-excluded analysis.
Further research: Material needed: The urate-analysis model is not filled using the post hoc PHS II gout analysis, HR model or prior-gout-excluded analysis. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on ITT/PP, adjustment, final values, changes, repeated measurement and analysis unit is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N15 · What are urate-outcome registration and prespecified hierarchy?

Current findings: The selected wording lacks the identity of urate-trial registration and plans.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: NCT00270647 is a cited identifier for the original PHS II cardiovascular/cancer trial. It is not transferred as preregistration of the relevant urate trial; plans remain unread in this work.
Required materials and conditions: Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes
Materials to obtain first: NCT00270647 is a cited identifier for the original PHS II cardiovascular/cancer trial. It is not transferred as preregistration of the relevant urate trial; plans remain unread in this work.
Further research: Material needed: NCT00270647 is a cited identifier for the original PHS II cardiovascular/cancer trial. It is not transferred as preregistration of the relevant urate trial; plans remain unread in this work. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Selected-trial registration, protocols, analysis plans, primary/secondary outcomes and changes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N16 · What is the background role of the post hoc PHS II report?

Current findings: The Juraschek2022 PHS II report, PMID35575611, PMCIDPMC9437983 and DOI10.1093/ajcn/nqac140 are retained as parent background context.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The report’s 454/517, 262/290, HRs and self-reported diagnoses are not transferred as direct serum-urate evidence.
Required materials and conditions: Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate
Materials to obtain first: The report’s 454/517, 262/290, HRs and self-reported diagnoses are not transferred as direct serum-urate evidence.
Further research: Material needed: The report’s 454/517, 262/290, HRs and self-reported diagnoses are not transferred as direct serum-urate evidence. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Gout-diagnosis reports, full-cohort/prior-gout-excluded analyses and an outcome distinct from urate is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01

N17 · What is the background role of the chronic-gout review?

Current findings: The Dietary interventions for chronic gout2021 citation, PMID34767649, is a parent note that vitamin C trials did not measure attack frequency.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The brief note does not establish urate effects, denominators, included trials, funding or plans and is not counted as a new direct trial.
Required materials and conditions: Cochrane2021 citation, unmeasured attacks and exact included trials
Materials to obtain first: The brief note does not establish urate effects, denominators, included trials, funding or plans and is not counted as a new direct trial.
Further research: Material needed: The brief note does not establish urate effects, denominators, included trials, funding or plans and is not counted as a new direct trial. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Cochrane2021 citation, unmeasured attacks and exact included trials must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Cochrane2021 citation, unmeasured attacks and exact included trials is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S02

N18 · What is known about contrary/null results, doses and populations?

Current findings: This 3020 account lacks positive/null urate-trial values and a complete condition-specific list.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: C54 alone does not establish consistent benefit or absence of null results. Gout-diagnosis findings are not transferred as conflicting urate results.
Required materials and conditions: Direct urate-trial positive/null findings, formulation, population, dose and intervals
Materials to obtain first: C54 alone does not establish consistent benefit or absence of null results. Gout-diagnosis findings are not transferred as conflicting urate results.
Further research: Material needed: C54 alone does not establish consistent benefit or absence of null results. Gout-diagnosis findings are not transferred as conflicting urate results. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Direct urate-trial positive/null findings, formulation, population, dose and intervals must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Direct urate-trial positive/null findings, formulation, population, dose and intervals is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N19 · Are independent replication and study totals established?

Current findings: The selected note refers to a separate surrogate verdict in 3019; the preserved input for this view is 3020.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Tables from 3019 are not combined as new independent replication. Parent PHS II/review material is not summed as urate trials or participants; unique totals remain unverified.
Required materials and conditions: Original urate reports, trial families, citation of 3019 and duplication
Materials to obtain first: Tables from 3019 are not combined as new independent replication. Parent PHS II/review material is not summed as urate trials or participants; unique totals remain unverified.
Further research: Material needed: Tables from 3019 are not combined as new independent replication. Parent PHS II/review material is not summed as urate trials or participants; unique totals remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Original urate reports, trial families, citation of 3019 and duplication must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Original urate reports, trial families, citation of 3019 and duplication is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N20 · Does urate reduction establish diagnosis prevention, fewer attacks or drug replacement?

Current findings: The existing account explains that urate reduction, attack prevention and standard-drug replacement each require separate evidence.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: The surrogate C54 grade is not repurposed as a grade for recurrent clinical attacks, first-diagnosis prevention or drug replacement.
Required materials and conditions: Separate questions for surrogate outcomes, clinical events and treatment replacement
Materials to obtain first: The surrogate C54 grade is not repurposed as a grade for recurrent clinical attacks, first-diagnosis prevention or drug replacement.
Further research: Material needed: The surrogate C54 grade is not repurposed as a grade for recurrent clinical attacks, first-diagnosis prevention or drug replacement. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Separate questions for surrogate outcomes, clinical events and treatment replacement must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Separate questions for surrogate outcomes, clinical events and treatment replacement is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N21 · What are long-term, dose and subgroup materials?

Current findings: The selected wording lacks dose, duration and population details beyond urate reduction.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Optimal dosing, sustained effects and population-specific effects are not filled using parent material or unmerged values from 3019.
Required materials and conditions: Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups
Materials to obtain first: Optimal dosing, sustained effects and population-specific effects are not filled using parent material or unmerged values from 3019.
Further research: Material needed: Optimal dosing, sustained effects and population-specific effects are not filled using parent material or unmerged values from 3019. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Baseline urate, deficiency, direct dosing, long-term/post-stopping follow-up and prespecified subgroups is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N22 · What are selected-trial funding, products, employees and interests?

Current findings: Funding, products and interests for the direct urate report are not linked in this 3020 account.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: PHS II NIH and BASF/Pfizer/DSM support→I1 is retained as parent wording, not transferred as independence of the relevant urate trial.
Required materials and conditions: Original urate-trial funding, products, packaging, employment and interests
Materials to obtain first: PHS II NIH and BASF/Pfizer/DSM support→I1 is retained as parent wording, not transferred as independence of the relevant urate trial.
Further research: Material needed: PHS II NIH and BASF/Pfizer/DSM support→I1 is retained as parent wording, not transferred as independence of the relevant urate trial. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Original urate-trial funding, products, packaging, employment and interests must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Original urate-trial funding, products, packaging, employment and interests is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N23 · How were harms collected for the selected exposure?

Current findings: Parent wording about high-dose oral C caution, gastrointestinal effects and limited event counts is retained as background.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Group-specific harms, collection, stopping and denominators for the selected urate trial remain unverified. Urate reduction is not used to judge safety.
Required materials and conditions: Urate-trial exposure, event collection, denominators, stopping and duration
Materials to obtain first: Group-specific harms, collection, stopping and denominators for the selected urate trial remain unverified. Urate reduction is not used to judge safety.
Further research: Material needed: Group-specific harms, collection, stopping and denominators for the selected urate trial remain unverified. Urate reduction is not used to judge safety. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Urate-trial exposure, event collection, denominators, stopping and duration must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Urate-trial exposure, event collection, denominators, stopping and duration is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N24 · What is known about predisposition, concomitant treatment, long-term and rare harms?

Current findings: Existing oral caution is retained; detailed harm material for the selected exposure is absent.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Specific interactions, causality, between-group risks, recovery after stopping and absence of long-term/rare harms remain unverified. No new incidence rate or verdict is created.
Required materials and conditions: Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure
Materials to obtain first: Specific interactions, causality, between-group risks, recovery after stopping and absence of long-term/rare harms remain unverified. No new incidence rate or verdict is created.
Further research: Material needed: Specific interactions, causality, between-group risks, recovery after stopping and absence of long-term/rare harms remain unverified. No new incidence rate or verdict is created. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Kidney disease, stones, iron overload, concomitant exposures, timelines, comparisons and long-term exposure is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N25 · Are the parent’s human-study indicator and selected axes distinguished?

Current findings: The parent’s no-human-study indicator is enabled, while the narrative says human studies exist and the indicator should be disabled. Both original records are retained.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: This is not corrected or inherited as a urate axis or a judgment of 0 human studies overall. Axes were not originally recorded for the selected urate subclaim.
Required materials and conditions: Disagreement between original indicator and narrative, and absent selected-subclaim axes
Materials to obtain first: This is not corrected or inherited as a urate axis or a judgment of 0 human studies overall. Axes were not originally recorded for the selected urate subclaim.
Further research: Material needed: This is not corrected or inherited as a urate axis or a judgment of 0 human studies overall. Axes were not originally recorded for the selected urate subclaim. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Disagreement between original indicator and narrative, and absent selected-subclaim axes must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Disagreement between original indicator and narrative, and absent selected-subclaim axes is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02

N26 · What records are the English subclaim, parent dates, deferral and empty corrections?

Current findings: Serum-urate reduction, the note about 3019, C54, parent Korean/English text, deferral, empty score,2026-09-07 and empty correction/deliberation records are retained. Production date is distinguished from completed content review.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summary, urate subclaim and parent bibliography read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Historical independent checks and the parent evidence date are not inherited as new urate full-text reading or completed content review.
Required materials and conditions: Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07
Materials to obtain first: Historical independent checks and the parent evidence date are not inherited as new urate full-text reading or completed content review.
Further research: Material needed: Historical independent checks and the parent evidence date are not inherited as new urate full-text reading or completed content review. This records needed materials; no new research was executed.
Remaining uncertainty: The selected urate trial’s population, product, dose, duration, comparator, design, measurement, effect, denominator, analysis, prespecification, independent replication, funding and harms are not directly linked in this record. Gaps are not filled using another question’s materials or a separate verdict’s values.
Conditions for verification: Original records on Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07 must link to the same urate question, population, product, comparison, measurement, time point and denominator, separately from background gout-diagnosis or attack material.
Why this condition is needed: Material on Original Korean/English subclaim, C54, parent deferral/empty score and2026-09-07 is needed to connect the selected urate question to its population, formulation, exposure, comparison, measurement, time point, denominator, precision and harms.
Application exceptions: The existing urate subclaim verdict C54 is preserved separately from parent flare-verdict deferral, empty score and assessment axes. Background gout-diagnosis HRs, events, denominators, duration and support are not transferred to urate effects or direct trials. No new effects, intervals, person-years, incidence rates, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and measurements, denominators, precision and harms.

Related sources S01 S02